This has a green to brown colour
What this means for you right now: BPC-157 and TB-500 are currently available through licensed compounding pharmacies under clinician supervision Thymosin Alpha-1 has a longer regulatory history and a more established compounding track record Sourcing from unregulated vendors carries real safety risks contamination, misdosing, and no quality control We've covered the full regulatory picture in detail here: PCAC Peptide Review 2026: What the July Advisory Panel Decision Means for BPC-157, TB-500, and Thymosin Alpha-1 What a Clinician-Supervised Long COVID Peptide Protocol Looks Like A responsible protocol starts with assessment not assumption
10.1007/s12035-022-02934-z 30
These compounds address underlying pathology including collagen disorganization, persistent inflammation, and impaired blood supply
Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, et al